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pDCsExperimental autoimmune encephalomyelitis (EAE) has been widely employed as a model to study
multiple sclerosis (MS) and indeed has allowed some important advances in our comprehension of MS
pathogenesis. Several pieces of evidence suggest that inﬁltrating Th1 and Th17 lymphocytes are
important players leading to CNS demyelination and lesion during the peak of murine EAE. Subsequently,
effector T cell responses rapidly decline and the recovery phase of the disease strongly correlates with the
expression of anti-inﬂammatory cytokines and the enrichment of Foxp3+ regulatory T (Treg) cells within
the target organ. However, the mechanisms leading to the increased presence of Treg cells and to the
remission phase of the disease are still poorly understood. Recent researches demonstrated that chemi-
cally induced amino-acid starvation response might suppress CNS immune activity. Here we veriﬁed an
important participation of the general control nonrepressible 2 (GCN2), a key regulator kinase of the
amino-acid starvation response, in the development of the remission phase of EAE in C57BL/6 mice. By
immunizing wild type C57BL/6 (WT) and GCN2 knock-out mice (GCN2 KO) with myelin oligodendrocyte
glycoprotein peptide (MOG35–55), it was noticed that GCN2 KO mice did not develop the remission phase
of the disease and this was associated with higher levels of CNS inﬂammation and increased presence of
effector T cells (Th1/Th17). These animals also showed lower frequency of Treg cells within the CNS as
compared to WT animals. Higher expression of indoleamine 2,3-dioxygenase (IDO) and higher frequency
of plasmacytoid dendritic cells (pDCs) were found at the peak of the disease in the CNS of WT animals.
Our results suggest that the GCN2 kinase-dependent sensing of IDO activity represents an important
trigger to the EAE remission phase. The IDO-mediated immunoregulatory events may include the arrest-
ing of effector T cell responses and the differentiation/expansion of Treg cells within the target organ.
 2013 Elsevier Inc. All rights reserved.1. Introduction 1992; Park et al., 2005). In EAE, Th17 cells are extensively foundFor several decades, murine experimental autoimmune enceph-
alomyelitis (EAE) has been studied as a model for immune-
mediated central nervous system (CNS) demyelinating diseases,
such as multiple sclerosis (MS) (Batoulis et al., 2011). Although
many of the cellular and molecular mechanisms involved in the
pathogenesis of these diseases are still not completely understood,
pieces of evidence from in vitro and in vivo studies suggest that
inﬁltrating Th1 and, most importantly, Th17 CD4+ lymphocytes
are signiﬁcant players leading to CNS inﬂammation and demyelin-
ation (Batoulis et al., 2011; Becher and Segal, 2011; Duong et al.,
1994; Komiyama et al., 2006; Langrish et al., 2005; Merrill et al.,in CNS demyelinating lesions and, in some particular cases, adop-
tive transference of this CD4+ T cell subset to susceptible animals
was shown to promote more severe symptoms than Th1 cells do
(Langrish et al., 2005). Moreover, less severe symptoms of the dis-
ease are displayed by mice that lack the Th17 signature cytokine
IL-17 (Komiyama et al., 2006) as well as by mice submitted to
the neutralizing action of anti-IL-17 antibodies (Langrish et al.,
2005).
In fact, it has been demonstrated that in C57BL/6 mice immu-
nized with MOG35–55, effector T cells start entering the CNS even
before the development of the clinical EAE symptoms and the fre-
quency of Th1 and Th17 cells in the target organ reaches the max-
imum around the peak of the disease (Korn et al., 2007; Murphy
et al., 2010). The peak is also characterized by intense activation
of microglia (Murphy et al., 2010) and recruitment of blood-
derived CD11b+ myeloid cells in a CCR2-dependent manner (Ajami
et al., 2011; Izikson et al., 2002). The peak is usually followed by a
remission phase in which the animals, although not displaying
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clinical signs. This remission phase is characterized by a decline
in effector Th1 and Th17 cells within the CNS and an enrichment
of Foxp3+ regulatory T (Treg) cells, which become much more fre-
quent in the target organ at this stage of the disease (Korn et al.,
2007). Rapid proliferation of Treg cells within the CNS has been
demonstrated at this time point during disease. This Treg cell pro-
liferation/expansion seems to drive a switch in the balance favor-
ing Treg activity over effector T cell responses and correlates
with recovery (O’Connor et al., 2007). Depletion of Treg cells has
been shown to inhibit the natural recovery from EAE, demonstrat-
ing that the enrichment of Treg cells within the CNS during the
course of EAE is essential for the occurrence of the remission phase
(McGeachy et al., 2005).
Although these observations may explain the kinetics of EAE,
describing an inﬂammatory proﬁle at the peak of the disease
followed by a regulatory stage that correlates with partial remis-
sion of the symptoms, the mechanisms triggering this shift are still
not completely understood. Moreover, recent researches demon-
strated that chemically induced GCN2-dependent amino-acid
starvation response might suppress CNS immune activity by
dampening Th17 cell responses (Sundrud et al., 2009).
Herein, we demonstrate that the GCN2 (general control nonre-
pressible 2) kinase, which is involved in the cellular amino acid
starvation response (AAR) (de Haro et al., 1996; Dever and
Hinnebusch, 2005), plays an important role as a trigger for the reg-
ulatory immune response that allows the development of the EAE
remission phase.2. Materials and methods
2.1. Mice
Foxp3GFP knockin mice (background C57BL/6) were described
elsewhere (Bettelli et al., 2006) and were kindly provided by
Dr. Howard L. Weiner, Center for Neurologic Diseases, Brigham
and Women’s Hospital, Harvard Medical School. GCN2-KO mice
(background C57BL/6) (Roffé et al., 2013) were kindly provided
by Prof. Beatriz Castilho, Federal University of Sao Paulo. Foxp3GFP
mice were crossed with GCN2-KO mice to obtain homozygous
GCN2-KO Foxp3GFP mice. Mice of 6–8 weeks old were used and
maintained under speciﬁc pathogen-free conditions in the animal
facilities at the Federal University of São Paulo. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the Brazilian
National Council of Animal Experimentation. The protocol was ap-
proved by the Committee on the Ethics of Animal Experimentation
at the Federal University of Sao Paulo.
2.2. Induction of EAE
EAE was induced by subcutaneous immunization with 200 lL
of an emulsion containing 200 lg of MOG35–55 peptide (MEVG-
WYRSPFSRVVHLYRNGK; Proteimax, Brazil) and 400 lg ofMycobac-
terium tuberculosis extract H37 Ra (Difco) in incomplete Freund’s
adjuvant oil. In addition, the animals received 200 ng of pertussis
toxin (Sigma–Aldrich) i.p. on day 0 and day 2. Clinical signs of
EAE were assessed according to the following score: 0, no signs
of disease; 1, loss of tone in the tail; 2, hindlimb paresis; 3, hind-
limb paralysis; 4, tetraplegia; 5, moribund.
2.3. Histopathology
Spinal cord tissue samples from MOG-immunized mice at the
peak (day 15) and remission (day 21) phases of EAE were collected,ﬁxed in 4% formaldehyde and parafﬁn-embedded. Sections of lum-
bar region were stained with hematoxylin and eosin (HE) or Luxol
Fast Blue to assess inﬂammatory inﬁltration and demyelination,
respectively.
2.4. Preparation of CNS mononuclear cells
Mice were perfused through the heart with cold PBS. Brain was
dissected and spinal cords ﬂushed out by hydrostatic pressure with
PBS. Central nervous system tissue was cut into pieces and di-
gested using Neural Tissue kit (P) (Miltenyi Biotec MACS). Mono-
nuclear cells were isolated by passing the tissue through a cell
strainer (70 lm), followed by a percoll (Sigma–Aldrich) gradient
(37%/70%) centrifugation. Mononuclear cells were removed from
the interphase, washed and suspended in PBS for FACS analysis.
2.5. Preparation of plasmacytoid dendritic cells (pDCs) and naïve T cell
Total splenic cells of Foxp3GFP or GCN2-KO-Foxp3GFP mice were
FACS stained and submitted to cell sorting. CD4+CD62L+GPF sub-
set was sorted as naïve T cells. pDCs were sorted as CD317+CD3
from C57BL/6 WTmice. Purity of sorted subsets was typically >98%
for naive T cells and >80% for pDCs. Cytometry antibodies were
purchased from eBioscience. All samples were sorted in the FACSA-
ria™ II (BD Biosciences).
2.6. Culture medium for in vitro assays
In vitro assays were performed in RPMI1640 medium supple-
mented with 10% FBS, 50 lM b-mercaptoethanol, 1 mM sodium
pyruvate, 1 mM nonessential amino acids, 2 mM L-glutamine, and
100 U/mL penicillin and 100 lg/mL streptomycin.
2.7. Plasmacytoid dendritic cells (pDCs) and naïve T cells co-culture
pDCs and naïve T cells were co-cultured as described (Matteoli
et al., 2010). Brieﬂy, 2  104 sorted pDCs were co-cultured with
1  105 WT or GCN2-KO naïve T cells in the presence of 1 lg/mL
soluble anti-mouse CD3e (eBioscience). Cells were cultured for
6 days. To promote Treg cell differentiation, 3 ng/mL of recombi-
nant TGF-b1 (R&D Systems) was added in the 4th day of culture.
Cells were then recovered and stained for FACS analysis.
2.8. In vitro differentiation of naïve T cells
Naïve T cells (3  105/well) WT or GCN2-KO were cultured for
5 days in presence of 1 lg/mL of plate-bound anti-mouse CD3e
and 2 lg/mL of soluble anti-CD28. For Th17 differentiation, the fol-
lowing was added to the culture: IL-1b (10 ng/mL), IL-6 (40 ng/mL),
IL-23 (10 ng/mL), TGF-b1 (2 ng/mL), TNFa (10 ng/mL), anti-mouse
IFN-c (10 lg/mL) and anti-mouse IL-4 (5 lg/mL); anti-mouse IL-2
(5 lg/mL) was added in the 3rd day. Th1 were differentiated in
the presence of IL-12 (40 ng/mL), IL-2 (20 ng/mL) and anti-mouse
IL-4 (5 lg/mL). Treg cells were generated by adding TGF-b1
(2 ng/mL). All recombinant cytokines were purchased from R&D
Systems and neutralizing antibodies from eBioscience.
2.9. Intracellular cytokine staining
For intracellular staining of cytokines, SNC mononuclear cells or
in vitro differentiated T cells were stimulated with PMA (50 ng/mL,
Sigma–Aldrich), Ionomycin (1 mM, Sigma–Aldrich) and Brefeldin A
(eBioscience) for 4 h. After staining of surface CD4, cells were ﬁxed
and made permeable using Cytoﬁx/Cytoperm and Perm/Wash buf-
fer from eBioscience according to the manufacturer’s instructions.
All antibodies to cytokines (IFN-c, IL-17) were obtained from
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sciences) and were analyzed by the software FlowJo, 9.3.3 version
(Tree Star, Inc.).
2.10. RNA isolation and quantitative RT-PCR
Total RNA of spinal cord and sorted CNS inﬁltrating T CD3+CD4+
cells was obtained by Trizol (Invitrogen) method following the
manufacturer’s instructions. cDNA was synthesized with Super-
Script II reverse transcriptase kit (Invitrogen). Gene expression
was evaluated by quantitative real-time PCR (qPCR) using the
SybrGreen-based system of detection (Applied Biosystems) and
the GAPDH gene as the reference for normalizations. Relative
expression was calculated by DDCt method (Schmittgen and Livak,
2008). We used 3 animals per group in each experiment. Reactions
were performed in triplicates and results are representative of at
least 2 independent experiments. Primer sequences: (50–30): Foxp3
F (50-CCTGGTTGTGAGAAGGTCTTCG-30) and Foxp3 R (50-TGCTCCA-
GAGACTGCACCACTT-30); GAPDH F (50-AAATGGTGAAGGTCGGT
GTG-30) and GAPDH R (50-TGAAGGGGTCGTTGATGG-30); T-bet F
(50-TCAACCAGCACCAGACAGAG-30) and T-bet R (50-ATCCTG-
TAATGGCTTGTGGG-30); IL-17a F (50-TCCAGAAGGCCCTCAGACTA-30)
and IL-17a R (50-TGAGCTTCC CAGATCACAGA-30); Rorc F (50-
GTGGAGTTTGCCAAGCGGCTTT-30) and Rorc R (50-CCTGCACATTCT-
GACTAGGACG-30); IFN-c F (50-ACAGCAAGGCGAAAAAGGAT-30)
and IFN-c R (50-TGAGCTCATTGAATGCTTGG-30); IL-10 F (50-ATC-
GATTTC TCCCCTGTGAA-30) and IL-10 R (50-TGTCAAATTCATT-
CATGGCCT-30) and IDO F (50-GCAGACTGTGTCCTGGCAAACT-30)
and IDO R (50-AGAGACGAGGAAGAAG CCCTTG-30), from Invitrogen.
2.11. Statistical analysis
Data are represented as mean ± SD. Statistical differences be-
tween groups was carried out using the unpaired Student’s t-test
or the Two-way ANOVA, followed by the Bonferroni test, where
appropriate. P-values of 60.05 were considered statistically signif-
icant. Statistical analysis was performed using GraphPad Prism
version 5.0 for Windows (GraphPad Software).3. Results
3.1. GCN2 kinase plays an important role in EAE remission
Clinical analysis of GCN2 KO and WT mice subjected to EAE
revealed that although no signiﬁcant differences were found be-
tween the two groups from the onset until the peak of the disease
(about 15 days post-immunization), signiﬁcant differences were
observed in the remission phase. In particular, from day 21 after
immunization, GCN2 KO showed higher clinical scores (ranging be-
tween 3.0 and 3.5) while WT mice, as expected, begun to decrease
the clinical symptoms (Fig. 1A). No signiﬁcant difference was found
in the disease incidence, which reached about 83% in WT and 88%
in GCN2-KO mice (Fig. 1B).
In an attempt to establish a correlation between clinical signs
and morphological changes in the CNS of EAE mice, histological
sections of lumbar spinal cord were collected at day 15 (peak)
and at day 21 (remission) after immunization and were analyzed
in light microscopy. We noticed an inﬂammatory inﬁltration
mainly composed by mononuclear leukocytes and predominantly
localized in the submeningeal areas and around blood vessels of
the white matter. The presence of the inﬂammatory cells was far
more evident in GCN2 KO mice, especially at the remission phase
of the disease (Fig. 2A and B). Likewise, although few morphologi-
cal differences were noted between the groups at day 15 post-
immunization (Supplemental Fig. 1), at day 21 post-immunization,GCN2 KO mice showed more pronounced demyelinating lesions,
evidenced by luxol fast blue staining (Fig. 2C and D). Thus, histo-
logical analyses gave support to the clinical data showing that ani-
mals lacking the GCN2 kinase do not present the remission phase
of EAE and this was associated with more intense inﬂammation
within the spinal cord.
3.2. The absence of EAE remission in GCN2-deﬁcient mice is associated
with increased expression of Th1- and Th17-related cytokines and
decreased expression of IL-10 and Foxp3 in the CNS
It has already been reported that in B6 mice, the partial remis-
sion following the peak of the disease is accompanied by a de-
crease in the frequency of CD4+ T effector cells expressing IFN-c
and/or IL-17 within the target organ (Korn et al., 2007; O’Connor
et al., 2007). We then asked whether in GCN2 KO mice, the ab-
sence of the remission phase and the more intense presence of
inﬂammatory cells would be associated with higher expression
of cytokines related to Th1 and Th17 cells. The characterization
of the cellular and the molecular proﬁle of the CNS inﬂammation
were performed by qPCR and ﬂow cytometric analyses of the inﬁl-
trating leukocytes. First, looking at the expression of transcripts
by qPCR, we found that, at the peak of the disease (15th day
post-immunization), GCN2 KO mice already had higher levels of
IL-17 and IFN-c mRNA in sorted CNS-inﬁltrating CD3+CD4+ T cells
than WT animals (Fig. 3A and B). Consistent with that, we also
found higher levels of expression for the transcriptional factors
Rorc (69% increase) and T-bet (12% increase) mRNA in CD4+ T
cells recovered from the CNS of GCN2-deﬁcient animals (Fig. 3C
and D). At day 21 post-immunization (remission phase), we ob-
served striking differences when comparing the expression of
inﬂammatory cytokines in sorted inﬁltrating T cells from WT mice
and GCN2 KO mice. The relative expression of IL-17 mRNA in
GCN2 KO mice was about 4 times higher and the expression of
IFN-c, Rorc and T-bet were, respectively 80%, 68% and 79% higher
than in WT mice (Fig. 3E–H). Flow cytometric analysis of CD4+ T
cells inﬁltrating the target tissue corroborated qPCR data. In fact,
at 21 days post-immunization, we also found an increased fre-
quency of effector T cells secreting IL-17 and/or IFN-c recovered
from the CNS of GCN2-deﬁcient mice (29.3%) as compared to that
noticed in WT animals (18.3%) (Fig. 3I–K). Overall, the data sug-
gests that GCN2 KO mice show more prevalent Th1 and Th17
CNS inﬁltration in EAE than WT do, in particular during the remis-
sion phase of the disease.
Increased frequency of regulatory T cells and the expression of
anti-inﬂammatory cytokines such as IL-10 have been associated
with EAE remission (Korn et al., 2007; O’Connor et al., 2007). Since
GCN2-deﬁcient mice developed a disease course in which the par-
tial remission does not occur, we asked if the increased expression
of Th1- and Th17-related cytokines would be associated with
downregulation of Foxp3+ T cells and/or IL10-secreting cells. Be-
cause CD4+ T cells might not be the only source of IL-10 during
EAE remission phase (Mann et al., 2007; Matsushita et al., 2008;
Ray et al., 2011), we decided to evaluate the presence of transcripts
for Foxp3 and IL-10 in the spinal cords instead of in inﬁltrating
CD4+ T cells. Indeed, we found that, in the remission phase of
EAE, GCN2 KO animals expressed lower levels of Foxp3 and IL-10
mRNA (about 55% less) (Fig. 4A and B). Conﬁrming the analysis
performed in CNS-inﬁltrating CD4+ T cells, we also observed higher
levels of IL-17 mRNA (about a four fold increase) in total spinal
cords of GCN2 KO animals as compared with WT mice (Supple-
mental Fig. 2). Once again, ﬂow cytometric analyses reinforced
the observations made in the qPCR experiments. Indeed, we ob-
served lower frequency of Foxp3GFP+ cells in gated CD3+CD4+ T
lymphocytes inﬁltrating the CNS of GCN2 KO Foxp3GFP mice
(18.7%) as compared to that in WT Foxp3GFP animals (30.4%)
Fig. 1. GCN2 is important to the development of EAE remission. (A) EAE clinical course and (B) percentage of EAE incidence in GCN2 KO and WT mice (representative of ﬁve
independent experiments performed with eight animals per group). Two-way Anova test. ⁄p < 0.05. Results are shown as mean ± standard deviation.
Fig. 2. GCN2-deﬁcient animals display intense inﬂammatory lesions and demyelination 21 days after MOG immunization. Inﬂammatory inﬁltration in the spinal cord of (A)
WT and (B) GCN2 KO mice 21 days post-immunization; demyelinating areas are indicated by (⁄) in the spinal cord of (C) WT and (D) GCN2 KO mice 21 days post-
immunization (representative of three independent experiments). H&E (A and B) and Luxol Fast Blue (C and D). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
180 H. Orsini et al. / Brain, Behavior, and Immunity 37 (2014) 177–186(Fig. 4C–E). It is important to mention that lower frequency of Treg
cells does not seem to be a general feature of GCN2 KO animals. In
fact, we did not observe differences in the peripheral (spleen and
lymph nodes) frequency of Foxp3GFP+ cells when comparing naïve
WT and GCN2 KO mice (Supplemental Fig. 3).
Taken together, these results suggest that GCN2 KO animals ex-
hibit higher pro-inﬂammatory responses within the CNS (mediated
by the action of Th1 and Th17 cells) than WT animals, especially in
the remission phase of EAE, which we demonstrated to be corre-
lated with lower IL-10 expression and diminished presence of
Foxp3+ regulatory T cells. In consequence, GCN2 KO mice develop
EAE characterized by the absence of the remission phase of the dis-
ease and also more accentuated inﬂammatory and demyelinating
lesions of the nervous tissue.
3.3. IDO expression within the CNS during EAE
The GCN2 kinase-dependent pathway is essential for cells to
sense the lack of tryptophan – or the presence of its metabolite
kynurenine – due to the activity of the enzyme indoleamine 2,3-
dioxygenase (IDO). Among immune cells, IDO has been reported
to be expressed by some antigen-presenting cells, in particular
plasmacytoid dendritic cells (pDC), and to play an important role
in immune regulation by promoting Foxp3+ T cell differentiationand by leading effector T cells to cell cycle arrest (Fallarino et al.,
2006; Munn et al., 2005). We ﬁrst sought to investigate the pres-
ence of pDC along the EAE course. We found that the frequency
of pDC among mononuclear cells inﬁltrating the CNS in EAE mice
is higher during the peak of the disease than during the remission
phase (Fig. 5A–D). We also found that naïve WT animals do not ex-
press high levels of IDO within the CNS and that along the EAE
course, IDO expression is much higher in the peak of the disease
than during the remission phase, when it is closer to that observed
in healthy animals. In fact, qPCR analysis revealed that the pres-
ence of IDO transcripts in the spinal cords of WT mice was about
18 times higher in the disease peak than in the remission phase
of EAE (Fig. 5E). Thus, our data suggests that IDO expression within
the CNS in EAE mice occurs during the period when inﬂammation
is highest. During the remission phase, when inﬂammation has al-
ready diminished in WT mice but not in GCN2 KO animals, we ob-
served a signiﬁcantly higher presence of transcripts for IDO in the
spinal cord from GCN2 KO mice as compared to that in the spinal
cord from WT mice (Fig. 5F); though the levels of IDO expression
veriﬁed during the remission phase in GCN2 KOmice are still lower
than that observed at the peak of the disease. It is also important to
mention that we did not ﬁnd differences in IDO expression within
the CNS between WT and GCN2 KO mice at the EAE peak (Supple-
mental Fig. 4).
Fig. 3. Absence of the remission phase in GCN2-deﬁcient animals is associated with higher Th1/Th17 response within the CNS. Relative expression of (A) IL-17, (B) IFN-c, (C)
Rorc and (D) T-bet in sorted CNS- inﬁltrating CD3+CD4+ T cells at the EAE peak (15th days post-immunization) and, respectively (E–H), at EAE remission stage (21st days
post-immunization). Representative plots showing the frequency of IL-17-positive and IFN-c-positive CNS inﬁltrating CD3+CD4+ T cells from (I) WT Foxp3GFP and (J) GCN2
KO Foxp3GFP mice at the remission phase (21 days post-immunization). (K) Statistical analysis of the plots shown in (I) and (J) (representative of four independent
experiments). Student’s t-test. ⁄p < 0.05. ⁄⁄p = 0.0076. ⁄⁄⁄p < 0.0001. Results are shown as mean ± standard deviation.
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expression, could be the trigger to promote regulatory T cell differ-
entiation/expansion within the CNS and to initiate the remission
phase during the course of EAE in WT mice. In contrast, GCN2 KO
animals are not able to sense IDO activity and that would lead, at
least in part, to a deﬁciency in the generation of regulatory T cells
and the consequent absence of the remission phase during the
course of the disease. In order to test this hypothesis we decided
to assess the ability of WT IDO-expressing pDCs to convert either
WT naïve T cells or GCN2-deﬁcient naïve T cells into Foxp3+ regu-
latory T cells. Indeed, we found that splenic WT pDCs puriﬁed by
cell sorting, when co-cultured with cell sorted anti-CD3 stimulated
WT CD4+CD62L+Foxp3GFP naïve T cells, can induce the conversion
of almost 8% of them into Foxp3GFP+ cells (Fig. 5G–I). In contrast,
only 3.7% of GCN2-deﬁcient naïve T cells could be converted into
Foxp3GFP+ cells when co-cultured with WT splenic pDCs
(Fig. 5G–I). Thus, the lack of the GCN2-dependent pathway in T
cells jeopardizes the pDC-induced conversion of these cells into
Foxp3+ regulatory T cells.3.4. In vitro differentiation of naïve CD4+ T lymphocytes into effector
or Foxp3+ regulatory cells
Finally, intending to evaluate if the results previously obtained
from in vivo experiments could be related to an intrinsic ability of
CD4+ T naïve cells from GCN2 KO mice to preferentially differenti-
ate into effector Th1/Th17 cells than into regulatory T lympho-
cytes, sorted naïve Foxp3GFPCD4+CD62L+ T lymphocytes from
WT Foxp3GFP mice and from GCN2 KO Foxp3GFP mice were
activated in vitro along with different polarizing conditions. Weobserved that, when activated in Th17-driving milieu, about 30%
of the naïve CD4+ T cells from GCN2 KO differentiated into IL-17-
producing cells. In contrast, only 21% of the WT naïve CD4+ T cells
became IL-17+ cells when activated in the same conditions
(Fig. 6A–C). In accordance with the reciprocal development of
Th17 and Foxp3+ regulatory T cells we observed the opposite when
naïve CD4+ T cells were activated in the presence of TGF-beta. In
this situation, while about 84% of the WT lymphocytes became
Foxp3+ cells, we observed about 78% of the GCN2-deﬁcient cells
differentiating into regulatory T cells (Fig. 6D–F). No difference
was noted in the differentiation of Th1 cells (Fig. 6G–I).4. Discussion
Despite the advances obtained in recent years, much remains to
be clariﬁed about the etiological and pathological events governing
inﬂammatory and demyelinating diseases of the CNS, such as MS.
Due to the limitation found in the development of more extensive
ante-mortem studies with humans, most of the information avail-
able is derived from animal models, such as murine EAE.
EAE is considered as a disease mediated primarily by the action
of Th1 and Th17 lymphocytes, which release several pro-inﬂam-
matory cytokines and chemokines with consequent mobilization
and activation of peripheral leukocytes to the CNS parenchyma
(Batoulis et al., 2011; Becher and Segal, 2011; Duong et al., 1994;
Komiyama et al., 2006; Langrish et al., 2005; Merrill et al., 1992;
Park et al., 2005). Thus, while the peak of the disease is character-
ized by the prevalence of effector T cells (Th1 and Th17), the remis-
sion phase is accompanied by an enrichment of Treg cells, which
become more frequent in the nervous tissue at this stage (Korn
Fig. 4. Absence of the remission phase in GCN2-deﬁcient animals is associated with lower frequency of Foxp3+ T cells within the CNS. Relative expression of (A) Foxp3 and (B)
IL-10 in total extracts of spinal cords from WT and GCN2 KO mice at the EAE remission phase (21 days post-immunization). Representative plots showing the frequency of
CNS-inﬁltrating Foxp3GFP+ CD4+ T (Treg) cells from (C) WT Foxp3GFP and (D) GCN2 KO Foxp3GFP mice at the EAE remission phase (21 days post-immunization). (E) Statistical
analysis of the plots shown in (C) and (D) (representative of four independent experiments). Student’s t-test. ⁄p = 0.017. Results are shown as mean ± standard deviation.
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between the presence of regulatory T cells and the regression of
EAE symptoms (McGeachy et al., 2005; O’Connor et al., 2007), since
their depletion inhibits the recovery of sick animals (McGeachy
et al., 2005). Also in MS, the frequency and function of regulatory
T cells appear to be inhibited, which could predispose the CNS to
inﬂammation and subsequent demyelination (Haas et al., 2005;
Venken et al., 2008; Viglietta et al., 2004).
The exact mechanisms by which the frequency of regulatory T
cells increases within the target organ to promote EAE remission
are still unclear. Herein we report that the GCN2 kinase plays an
important role in triggering EAE remission, likely due to IDO-
induced differentiation and/or expansion of Foxp3+ regulatory
T cells.
GCN2 kinase plays a pivotal role in the cellular amino acid star-
vation response (AAR) and its activation occurs via the presence of
amino acid uncharged tRNA, leading to decreased protein synthesis
via phosphorylation of eIF2a (de Haro et al., 1996; Dever and Hin-
nebusch, 2005). This GCN2-dependent pathway exerts important
functions controlling cell growth and/or differentiation (de Haro
et al., 1996). In particular, considering immune cells, the GCN2-
dependent pathway represents an essential sensor for theimmunomodulatory effects elicited by the enzymatic activity of
indoleamine 2,3-dioxygenase (IDO), which promotes tryptophan
starvation due to its catabolism into kynurenine. In fact, it was al-
ready demonstrated that IDO-expressing plasmacytoid dendritic
cells (pDCs) activate the GCN2 kinase pathway in T cells suppress-
ing their proliferation upon TCR stimulation (Munn et al., 2005).
Moreover, IDO induced profound anergy in responding WT T cells,
but GCN2-knockout cells were refractory to IDO-induced anergy
(Munn et al., 2005). In murine CD8+ T cells, IDO activity seems to
result in GCN2 kinase-dependent down-regulation of the TCR
zeta-chain. TCR zeta down-regulation could be demonstrated
in vivo and was associated with an impaired cytotoxic effector
function in vitro (Fallarino et al., 2006). Tryptophan catabolism
has also been shown to induce apoptosis in thymocytes and Th1
cells (Fallarino et al., 2002). Recently, GCN2-dependent activation
of the amino acid starvation response was found to inhibit mouse
and human Th17 differentiation (Sundrud et al., 2009). Besides
dampening the response of effector T cells, IDO-induced regulatory
mechanisms also involve de novo generation/expansion of Foxp3+
regulatory T cells (Baban et al., 2009; Matteoli et al., 2010). Hence,
it has been demonstrated that IDO-expressing DCs can induce
Foxp3 expression when co-cultivated with Foxp3CD4+CD25 T
Fig. 5. IDO expression and pDC frequency within the CNS increase during EAE peak. Representative plots showing the frequency of pDCs (CD317+ cells) gated from (A) WT
CD45+CD11b inﬁltrating CNS cells at the EAE peak (B) and remission (C) stages (representative of three independent experiments). (D) Statistical analysis of representative
data shown in (B) and (C). Student’s t-test. ⁄⁄p = 0.0035. (E) Relative expression of IDO in spinal cord extracts from healthy and sick WT mice at the EAE peak and remission
stages. (F) Relative expression of IDO in spinal cord extracts from WT and GCN2 KO mice at the remission stage of EAE. Two-way ANOVA and Student’s t-test. ⁄⁄p = 0.0071.
⁄⁄⁄p < 0.0001. Representative plots showing the frequency of Foxp3GFP+ T cells differentiated in vitro from WT Foxp3CD4+CD62L+ naïve T cells (G) or from GCN2 KO
Foxp3CD4+CD62L+ naïve T cells (H) co-cultured with WT pDCs. (I) Statistical analysis of representative data shown in (G) and (H) (representative of three independent
experiments made in triplicate). Student’s t-test. ⁄p = 0.038. All results are shown as mean ± standard deviation.
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tion that the IDO-induced regulatory T cells indeed displayed sup-
pressive activity in in vitro and in vivo assays (Fallarino et al., 2006).
In a similar way, in vitro activation of lymphocytes in the presence
of a tryptophan metabolite (3-HAA) promoted Treg differentiation
(Chen et al., 2008). In vivo, IDO-expressing plasmacytoid DCs are
also thought to create a profoundly suppressive microenvironment
within tumor-draining lymph nodes via constitutive activation of
regulatory T cells (Katz et al., 2008; Sharma et al., 2007). Finally,
IDO-expressing DCs in the gut are also thought to play an impor-
tant role in oral tolerance by promoting the differentiation of
antigen-speciﬁc Treg cells (Matteoli et al., 2010).
Although many cell types can potentially express IDO, includ-
ing non-hematopoietic cells such as ﬁbroblasts and endothelial
cells, among hematopoietic cells, the expression of IDO is often
restricted to certain speciﬁc antigen-presenting cell subsets that
appear specialized for upregulation of IDO in response to inﬂam-
matory stimuli. In particular, IDO expression has been well doc-
umented in pDCs. In fact, it has been demonstrated that in
these cells, IDO is mainly induced by Toll-like receptor ligands
(Baban et al., 2011; Volpi et al., 2012) and by cytokines such as
IFN-c (Mellor and Munn, 2004) and TNF-a (Kwidzinski et al.,
2005).
In EAE, as well as in other inﬂammatory conditions, IFN-c and
TNF-a are highly expressed especially in the peak of the disease,
when there is a predominance of effector T cells and other acti-
vated leukocytes within the CNS. Interestingly, in our experiments
we observed that IDO expression in the CNS of WT animals is high-
er in the peak of the disease than in the remission phase, when IDOlevels were comparable to that found in naïve mice. In addition, we
observed higher frequency of pDCs in the CNS of WT animals also
at the peak of the disease and a subsequent decrease in their fre-
quency at the remission stage. In EAE, it was shown that depletion
of pDCs during relapse phases of the disease resulted in exacerba-
tion of clinical severity. Moreover, pDC depletion signiﬁcantly
enhanced CNS T cell activation, as well as IL-17 and IFN-c produc-
tion (Bailey-Bucktrout et al., 2008). In a similar way, another study
showed that pDCs depletion 1 week after MOG immunization in-
creased the clinical signs of the disease, indicating its immuno-
modulatory role at this stage (Isaksson et al., 2009). These
observations may suggest that the increase in IDO expression at
the peak of the disease, likely due to pro-inﬂammatory mediators
that are present in the nervous tissue at this stage, initiates disease
recovery by activating the GCN2 pathway, which in turn stimulates
immunoregulatory responses involving apoptosis and/or anergy of
effector T cells and induction and/or hyper-activation of Treg cells.
In fact, we showed that, in contrast to what happens in WT mice in
which the remission phase develops normally, animals that are un-
able to sense IDO activity due to the absence of the GCN2 kinase do
not present the remission phase and this was associated to more
pronounced inﬂammation, higher frequency of effector T cells,
and lower frequency of regulatory T cells within the CNS. Although
we have found a temporal association between IDO expression and
frequency of pDCs at the peak of EAE in the CNS of WT animals, it is
important to mention that other cells such as astrocytes (Guillemin
et al., 2005; Suh et al., 2007) and microglia (Guillemin et al., 2005;
O’Connor et al., 2009; Wang et al., 2010) can also express IDO with-
in the inﬂamed CNS.
Fig. 6. GCN2-deﬁcient naïve T cells are more prone to differentiate into Th17 cells. Frequency of Th17 cells differentiated in vitro from CD4+CD62L+ T naïve cells from (A)
GCN2 KO and (B) WT mice. (C) Statistical analysis of the representative data shown in (A) and (B). Frequency of Treg (Foxp3GFP+) cells differentiated in vitro from
Foxp3CD4+CD62L+ T cells from (D) GCN2 KO Foxp3GFP and (E) WT Foxp3GFP mice. (F) Statistical analysis of the representative data shown in (D) and (E). Frequency of Th1
cells differentiated in vitro from CD4+CD62L+ T cells from (G) GCN2 KO and (H) WT mice and (I) statistical analysis of the representative data shown in (G) and (H).
Representative of three independent experiments made in triplicate. Student’s t-test. ⁄⁄⁄p < 0.0001. Results are shown as mean ± standard deviation.
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suggested in a study comparing disease severity in WT and IDO
knockout mice (Yan et al., 2010). It was found that the absence of
the enzyme promotes more severe symptoms of the disease associ-
ated with higher encephalitogenic response of Th1 and Th17 cells
and decreased presence of Treg cells. Moreover, Sakurai et al.
(2002) found that the treatment of animals subjected to passive
EAE with 1-Methyl-DL-tryptophan (1-MT), which inhibits IDO
enzymatic activity, augmented the mean maximal clinical score of
the disease. Another study also found that IDO inhibition by sys-
temic administration of 1-MT at clinical onset signiﬁcantly exacer-
bated disease scores at the peak of the disease (Kwidzinski et al.,
2005). Accordingly, treating mice with tryptophan metabolites
has been shown to improve EAE symptoms (Platten et al., 2005;
Yan et al., 2010). In agreement with our data, one of these studies
also reported increased IDO activity within the CNS during the peak
of the disease (Kwidzinski et al., 2005). Curiously, at late stages of
the disease, we observed a signiﬁcant increase in IDO expression
in the spinal cords from GCN2 KO animals as compared to that in
WTmice. This ﬁnding also gives support to our suggestion that upon
ongoing inﬂammation (that is continuous in GCN2-deﬁcient mice)
IDO is probably stimulated to promote homeostatic balance. Thus,
when sensing IDO activity fails because of the lack of GCN2, higherlevels of inﬂammatory mediators are maintained, keeping the in-
creased expression of IDO by the cells inﬁltrating the nervous tissue.
Consistently with the literature (Fallarino et al., 2006; Munn
et al., 2005), the data from the in vitro experiments we carried
out demonstrated that pDCs fromWT mice promote more efﬁcient
differentiation of Treg cells from naïve T CD4+ lymphocytes than
from GCN2-KO T cells, thus conﬁrming that the pDCs-mediated
differentiation of regulatory T cells is likely to depend on the ability
of T cells to sense IDO activity. Unexpectedly, our in vitro experi-
ments also demonstrated that naïve CD4+CD62L+ T cells from
WT mice, when activated in the presence of TGF-b, differentiated
more frequently into Treg cells than those from GCN2 KO animals.
In accordance with the described reciprocal developmental path-
ways for the generation of Treg and Th17 cells (Bettelli et al.,
2006), we also observed that the naïve T cells from GCN2 KO mice
are more prone to differentiate into Th17 cells. Although this
observation highlights a possible involvement of GCN2 in the
dichotomy characterizing the differentiation of effector Th17 and
regulatory T cells by mechanisms that were not elucidated, it
might help explaining the higher expression of effector cytokines
in the CNS of GCN2 KO animals already at EAE peak.
Altogether, our results suggest that the pro-inﬂammatory
events mediated by Th1 and Th17 cells that lead animals to
H. Orsini et al. / Brain, Behavior, and Immunity 37 (2014) 177–186 185develop the clinical symptoms characterizing the peak of the dis-
ease (especially the high expression of IFN-c and TNF) promote
the activation of IDO in APCs within the CNS, such as inﬁltrating
pDCs. The enzymatic activity of IDO results in activation of GCN2
which in turn works as a trigger for immunomodulatory events
(such as Treg cell differentiation and suppression of effector T cell
responses), leading to a partial remission in the clinical signs of the
disease. The absence of GCN2 prevents the suppressor functions
of IDO, making the environment permissive to continued
inﬂammation in EAE mice.Acknowledgment
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